Clinical and immunological features of the atopic dermatitis in children

   Background: “atopic march” (AM) is the natural history of allergy mostly in children.

   The aim: to describe the production of biomarkers of allergic inflammation in dependence on the duration of AD.

   Patients and methods. 94 children suffered from atopic dermatitis (AD) have been included to the study. The severity of the disease has been estimated, serum level of total IgE, IL- 4, interferon gamma and sIL- 2R have been estimated.

   Results. Coexistence of AR and AD was diagnosed in 32/94 (34.0 %) patients. Less severity of AD (SCORAD 32.3 ± 9.17 score vs 22.2 ± 2.29 score, p < 0.05), but higher serum level of total IgE (Ме 123 [Q1- Q3 67–156] IU/ml vs Ме 53 [Q1- Q3 5–108] IU/ml, р < 0.001), IL- 4 (Ме 12.0 [Q1- Q3 8.7–16.1] pg/ml vs Me 6.0 [Q1- Q3 2.2–12.1] pg/ml, р = 0.04) and sIL- 2R (Ме 2.1 [Q1- Q3 0–20] IU/ml vs Me 0 [Q1- Q3 0–12.9] IU/ml, р = 0.34) are detected in comorbid patients. Eposides of wheezing are associated with additional risk of AD (OR 2.3 [95 % CI 1, 18–4,54]).

   Discussion. The development of AR in children with AD is considered as progression of natural history of allergy. In our study it was associated with higher level of IgE, IL- 4 and sIL- 2R. At the same time the comorbid patients had less severity of AD.

   Conclusion. The coexistence of AD and AR in 3- year-old children is associated with less severity of skin symptoms but higher frequency of sensitization to inhalant allergens than in AD. AM is accompanied by higher production of Th2- dependent parameters and markers of early activation of T- cells. The probability of the AM is higher in 2 times if there were wheezing episodes in the anamnesis.

1. Cohen S, Dworetzky M, Frick OL. Coca and Cooke on the classification of hypersensitiveness. J Allergy Clin Immunol. 2003 Jan; 111 (1): 205–210. doi: 10.1067/mai.2003.106.

2. Yaneva M, Darlenski R. The link between atopic dermatitis and asthma — immunological imbalance and beyond. Asthma Research and Practice. 2021 Dec 15; 7 (1): 16. doi: 10.1186/s40733-021-00082-0.

3. WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. 2001. Available online: http://www.inchem.org/documents/ehc/ehc/ehc222.htm (accessed on 20 June 2022).

4. Thijs J, Krastev T, Weidinger S, Buckens CF, De Bruin- Weller M, Bruijnzeel- Koomen C, Flohr C, Hijnen D. Biomarkers for atopic dermatitis: A systematic review and meta- analysis. Allergy Clin Immunol. 2015 Oct; 15 (5): 453–460. DOI: 10.1097/ACI.0000000000000198.

5. Mastraftsi S, Vrioni G, Bakakis M, Nicolaidou E, Rigopoulos D, Stratigos AJ, Gregoriou S. Atopic Dermatitis: Striving for Reliable Biomarkers. J. Clin. Med. 2022 Aug 9; 11 (16): 4639. doi: 10.3390/jcm11164639.

6. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu atopicheskogo dermatita. — M.: Rossijskaya associaciya allergologov i klinicheskih immunologov, 2020. — 81 s. (In Russ.)

7. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu allergicheskogo rinita. — M.: Rossijskaya associaciya allergologov i klinicheskih immunologov, 2020. — 56 s. (In Russ.)

8. Alduraywish SA, Lodge CJ, Campbell B, et al. The march from early life food sensitization to allergic disease: a systematic review and meta-analyses of birth cohort studies. Allergy. 2016; 71: 77–89. 2016 Jan; 71 (1): 77–89. doi: 10.1111/all.12784. Epub 2015 Nov 4.

9. Zhitnikovskaya АL, Lepeshkova TS. Osobennosti sensibilizacii detej s atopicheskim dermatitom. Allergologiya i immunologiya v pediatrii. 2022; 1: 34–35. doi: 10.53529/2500- 1175-2022-1-34-35. (In Russ.)

10. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018 Feb; 120 (2): 131–137. doi: 10.1016/j.anai.2017.10.037.

11. Namazova- Baranova LS, Snovskaya MA, Mityushin IL, Kozhevnikova OV, Batyrova AS. Osobennosti diagnostiki allergii u detej. Vestnik RAMN. 2017; 72 (1): 33–41. doi 10.15690/vramn799. (In Russ.)

12. Gaparkhoeva ZM, Seliverstova EN, Stroikova TR, Bashkina OA, Demidova LV. Sovremennye predstavleniya o roli geneticheskih prediktorov pri bronhial’noj astme u detej. Astrahanskij medicinskij zhurnal. 2015; 10 (01): 6–11. (In Russ.)

13. Aw M, Penn J, Gauvreau GM, Lima H, Sehmi R, Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020; 181 (1): 1–10. doi: 10.1159/000502958. Epub 2019 Oct 8.

14. Ni Wang, Schoos A-MM, Larsen JM, Brix S, Thysen AH, Rasmussen MA, Stokholm J, Bønnelykke K, Bisgaard H, Chawes BL. Reduced IL-2 response from peripheral blood mononuclear cells exposed to bacteria at 6 months of age is associated with elevated total-IgE and allergic rhinitis during the first 7 years of life. Bio Medicine. 2019 May; 43: 587–593. doi: 10.1016/j.ebiom.2019.04.047. Epub 2019 May 2.

15. Utomo BSR, Hatta M, Sirait RH, Pratiwi S, Massi MN. The Role of Cytokine Interleukin- 2, Transcription Factor of FoxP3 in the Immunological Regulation of Allergic Rhinitis. International Journal of Otolaryngology and Head & Neck Surgery. 2018 Jan 07 (01): 7–19. DOI: 10.4236/ijohns.2018.71002.

16. Belan EB, Sadchikova TL, Antonov YuV. Dinamika urovnya sIL-2R v syvorotke krovi na rannih etapah provedeniya allergen-specificheskoj immunoterapii. Medicinskaya immunologiya. 2009; 11 (4–5): 346–347. (In Russ.)

17. Belan EB. Farmakologicheskaya profilaktika bronhial’noj astmy u detej: diss. ... doktora medicinskih nauk: 14.00.25 / E. B. Belan. — Volgograd, 2006. — 333 s. (In Russ.)

18. Armentia A. Usefulness of Measurement of Soluble Interleukin- 2 Receptor (sIL- 2R) and Interleukin 6 to Monitor Efficacy of Specific Immunotherapy in Eosinophilic Esophagitis. International Journal of Medical Research & Health Sciences. 2021; 10 (2): 173–179. ISSN No: 2319- 5886.